Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

KPTI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Karyopharm Therapeutics Inc.NASDAQ: KPTI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $1.36M rose 4.3% year over year, behind the +9.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.

Context

  • Cost of revenue amounted to 4.1% of revenue in FY2025, unchanged from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +4.3% toward the trailing-twelve-month pace of +9.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.36M-8.6% QoQ
Last fiscal yearDec 2025
$5.95M-1.0% YoY
LTMMar 2026
$6.01M+9.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%——
1 year-1.0%——
3-year CAGR+4.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
5.95M USD
Year-over-year change
-1.0%
4-year CAGR
+15.0%

Cost of Revenue vs competitors

How KPTI compares with its peers on the latest reported figures

  • KPTI's LTM Mar 2026 cost of revenue of $6.01M is the highest of the 4 companies compared; the peer median is $108K.
  • Its year-over-year change of +9.4% is the highest of 2, against a peer median of -69.5%.
  • Cost of revenue amounts to 4.0% of revenue for KPTI, versus a peer median of 20.6%.
KPTI Competitors Peer median
Cost of Revenue for KPTI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$6.01M +9.4%+4.5%4.0%
XFORX4 Pharmaceuticals, Inc.LTM Mar 2026$1.85M -69.5%—20.6%
INMBINmune Bio, Inc.LTM Mar 2026$108K ———
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding KPTI) $108K-69.5%—20.6%

Competitors are the stored peer set for KPTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue209.82M157.07M146.03M145.24M146.07M
Cost of Revenue3.4M5.21M4.94M6.01M5.95M
Gross Profit206.42M151.86M141.09M139.23M140.12M
Gross Margin98.4%96.7%96.6%95.9%95.9%
Research & Development160.84M148.66M138.75M143.23M125.62M
Selling, General & Admin143.85M145.4M131.88M115.44M105.21M
Operating Expenses304.69M294.06M270.63M258.67M230.83M
Depreciation & Amortization789K621K530K340K296K
EBITDA(96.99M)(139.31M)(118.42M)(38.6M)(149.85M)
EBITDA Margin-46.2%-88.7%-81.1%-26.6%-102.6%
Operating Income(98.27M)(142.2M)(129.54M)(119.44M)(90.71M)
Operating Margin-46.8%-90.5%-88.7%-82.2%-62.1%
Interest Income582K2.36M10.94M7.4M2.77M
Interest Expense26.05M25M23.82M37.42M45.85M
Other Income / Expenses(25.55M)(22.72M)(13.24M)43.08M(105.29M)
Income Before Tax(123.82M)(164.92M)(142.78M)(76.37M)(196M)
Pre-Tax Margin-59.0%-105.0%-97.8%-52.6%-134.2%
Income Tax Expense268K369K323K57K43K
Net Income(124.09M)(165.29M)(143.1M)(76.42M)(196.04M)
Net Margin-59.1%-105.2%-98.0%-52.6%-134.2%
EPS (Basic)(24.75)(30.28)(18.79)(9.41)(17.93)
EPS (Diluted)(24.75)(30.28)(18.79)(9.41)(17.93)
Weighted Avg Shares5.01M5.46M7.61M8.12M10.94M
Weighted Avg Shares (Diluted)5.01M5.46M7.61M8.12M10.94M

Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Intrinsic Alpha fair value

Locked

Current Price

$7.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.